Eterna Therapeutics Completes Name Change, Acquires Option to License iPSC-Derived NK and T Cell Therapies from Exacis Biotherapeutics
October 17, 2022 08:30 ET
|
Eterna Therapeutics Inc.
The Eterna corporate mission is to realize the potential of cell engineering to provide patients with transformational new medicines Exacis’ iNK and iT cells, made using non-viral, episome-free cell...
Brooklyn ImmunoTherapeutics Announces Name Change to Eterna Therapeutics and Provides Corporate Updates
October 11, 2022 08:30 ET
|
Brooklyn ImmunoTherapeutics, Inc.
New name reflects Company focus on leveraging exclusively in-licensed foundational mRNA cell engineering patent portfolio The Eterna corporate mission is to realize the potential of cell engineering...
Brooklyn ImmunoTherapeutics Announces Results of Phase 2 Study of IRX-2 in Head and Neck Cancer
July 26, 2022 07:30 ET
|
Brooklyn ImmunoTherapeutics, Inc.
SAN DIEGO, July 26, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (Nasdaq:BTX) (“Brooklyn” or the “Company”) today announces results from the INSPIRE phase 2 trial of IRX-2, a...
Brooklyn ImmunoTherapeutics Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency
June 17, 2022 17:00 ET
|
Brooklyn ImmunoTherapeutics, Inc.
SAN DIEGO, June 17, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (Nasdaq:BTX) (“Brooklyn” or the “Company”), a biopharmaceutical company focused on developing advanced therapies using...
Brooklyn ImmunoTherapeutics Announces Board Changes
June 07, 2022 07:30 ET
|
Brooklyn ImmunoTherapeutics, Inc.
SAN DIEGO, June 07, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (Nasdaq:BTX) (“Brooklyn” or the “Company”), a biopharmaceutical company focused on exploring the role that cytokine,...
Brooklyn ImmunoTherapeutics Announces Changes to Executive Management: Matt Angel, Ph.D. Appointed Interim Chief Executive Officer and President, Andrew Jackson Appointed Chief Financial Officer Postpones 2022 Annual Meeting
May 31, 2022 07:30 ET
|
Brooklyn ImmunoTherapeutics, Inc.
SAN DIEGO, May 31, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (Nasdaq:BTX) (“Brooklyn” or the “Company”), a biopharmaceutical company focused on exploring the role that cytokine,...
Brooklyn ImmunoTherapeutics Announces Receipt of Notice from Nasdaq Regarding Delayed Filing of Quarterly Report on Form 10-Q
May 27, 2022 16:30 ET
|
Brooklyn ImmunoTherapeutics, Inc.
SAN DIEGO, May 27, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (Nasdaq:BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine, gene editing, and...
Brooklyn ImmunoTherapeutics Announces Establishment of New Research and Development Facility for Advancement of Engineered Cellular Medicines
April 21, 2022 07:30 ET
|
Brooklyn ImmunoTherapeutics, Inc.
SAN DIEGO, April 21, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (Nasdaq:BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine, gene editing, and...
Brooklyn ImmunoTherapeutics Announces Fourth Quarter and Full Year 2021 Financial Results
April 15, 2022 16:15 ET
|
Brooklyn ImmunoTherapeutics, Inc.
SAN DIEGO, April 15, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (Nasdaq:BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine, gene editing, and...
Brooklyn ImmunoTherapeutics Announces Closing of $12 Million Private Placement
March 09, 2022 16:15 ET
|
Brooklyn ImmunoTherapeutics, Inc.
NEW YORK, March 09, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (Nasdaq: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine, and gene...